Belgium · Delayed Price · Currency is EUR Ion Beam Applications Earnings Call Transcripts
Fiscal Year 2025
-
Record 2025 revenue and EBIT were driven by strong backlog conversion, proton therapy profitability, and strategic investments. Guidance for 2026 targets further EBIT growth and margin improvement, with legacy contract impacts expected to diminish and cash position to improve by 2027.
-
Order intake and backlog remain strong, supporting confidence in meeting EBIT guidance of at least $25 million. New financing enhances balance sheet flexibility, while segment performance is robust despite some headwinds in Dosimetry.
-
Revenue surged 40% year-over-year to EUR 304.9 million, driven by strong backlog conversion and growth across all business units, though gross margin declined due to legacy projects. Guidance for 2025 is reaffirmed, with a minimum EUR 25 million rebit and positive outlook for proton therapy profitability.
-
Strong competitive positioning, robust innovation, and a balanced global presence underpin growth. Financial guidance targets 5%-7% annual revenue growth and 10% EBIT margin by 2028, driven by margin normalization, service scale, and capital-light investments. Proton therapy adoption is set to accelerate with new clinical evidence and innovations.
Fiscal Year 2024
-
Record 2024 revenue of EUR 498 million (+7% YoY) and a return to profitability were driven by strong backlog conversion and growth in Other Accelerators. Updated guidance targets at least EUR 25 million REBIT in 2025 and 5-7% CAGR through 2028, with prudent R&D investment and a focus on sustainable margins.
-
Revenue grew 22% to €206.5M, with improved margins and a reduced net loss of €10.3M. Backlog conversion accelerated, especially in proton therapy and other accelerators, while the outlook remains strong with midterm EBIT margin targets reiterated.